Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P57059

UPID:
SIK1_HUMAN

ALTERNATIVE NAMES:
Salt-inducible kinase 1; Serine/threonine-protein kinase SNF1-like kinase 1

ALTERNATIVE UPACC:
P57059; A6NC84; Q5R2V5; Q6ZNL8; Q86YJ2

BACKGROUND:
The Serine/threonine-protein kinase SIK1, known for its roles in tumor suppression and regulation of metabolic processes, is crucial for phosphorylating key proteins involved in cell detachment-induced apoptosis and metabolic regulation. By modulating the activity of CREB-specific coactivators and histone deacetylases, SIK1 influences muscle differentiation, gluconeogenesis, and lipogenesis, marking its importance in cellular homeostasis and growth.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Developmental and epileptic encephalopathy 30, SIK1 represents a promising avenue for drug discovery. Exploring SIK1's mechanisms could lead to breakthrough therapies for epilepsy and related neurodevelopmental impairments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.